K. Thompson

发表

Molecular Mechanisms of Action of Bisphosphonates: Current Status

M. Rogers, A. Roelofs, K. Thompson, 2006, Clinical Cancer Research.

IL-23 Inhibits Osteoclastogenesis Indirectly through Lymphocytes and Is Required for the Maintenance of Bone Mass in Mice1

T. Martin, N. Sims, M. Gillespie, 2008, The Journal of Immunology.

Cytosolic entry of bisphosphonate drugs requires acidification of vesicles following fluid-phase endocytosis

M. Rogers, J. Crockett, F. Coxon, 2006 .

Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.

C. Poulter, M. Rogers, S. P. Luckman, 2001, The Journal of pharmacology and experimental therapeutics.

Bisphosphonates and [gamma][delta] t-cells: New insights into old drugs

M. Rogers, K. Thompson, 2006 .

Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP

J. Mönkkönen, H. Mönkkönen, A. Roelofs, 2009, British journal of haematology.

Characterisation of gamma delta (γδ) T cell populations in patients with sepsis

N. Webster, H. Galley, K. Thompson, 2015, Cell biology international.

The Molecular Mechanisms of Action of Bisphosphonates

M. Rogers, K. Thompson, 2007 .

Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.

M. Rogers, J. Dunford, F. Ebetino, 2002, Biochemical and biophysical research communications.

Alkylamines and bisphosphonates: a common mechanism for activation of

K. Thompson, M. Rogers, 2009 .

the mevalonate pathway 2 T-cell activation and proliferation by inhibiting δ 9V γ Alkylamines cause V

M. Rogers, K. Thompson, Javier Rojas-Navea, 2013 .

Brief report Alkylamines cause V (cid:1) 9V (cid:2) 2 T-cell activation and proliferation by inhibiting the mevalonate pathway

M. Rogers, K. Thompson, Javier Rojas-Navea, 2005 .

Novel immunostimulatory effects of osteoclasts and macrophages on human γδ T cells

K. Thompson, A. Pappalardo, 2015, Bone.

Activation of γδ T cells by bisphosphonates.

J. Mönkkönen, M. Rogers, H. Mönkkönen, 2010, Advances in experimental medicine and biology.

Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.

M. Rogers, F. Coxon, F. Ebetino, 2008, Bone.

Recent advances in understanding the mechanism of action of bisphosphonates.

M. Rogers, F. Coxon, K. Thompson, 2006, Current opinion in pharmacology.

Cytosolic Entry of Bisphosphonate Drugs Requires Acidification of Vesicles after Fluid-Phase Endocytosis

M. Rogers, J. Crockett, F. Coxon, 2006, Molecular Pharmacology.

Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages.

M. Rogers, F. H. Ebetino, F. Coxon, 2010, Current pharmaceutical design.

Alkylamines cause Vγ9Vδ2 T-cell activation and proliferation by inhibiting the mevalonate pathway

M. Rogers, K. Thompson, Javier Rojas-Navea, 2006 .

Alkylamines cause Vgamma9Vdelta2 T-cell activation and proliferation by inhibiting the mevalonate pathway.

M. Rogers, K. Thompson, Javier Rojas-Navea, 2006, Blood.

Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.

M. Rogers, K. Thompson, 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Statins Prevent Bisphosphonate‐Induced γ,δ‐T‐Cell Proliferation and Activation In Vitro

M. Rogers, K. Thompson, 2003 .

Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women.

D. Reid, W. Simpson, M. Rogers, 2009, Bone.

Activation of gammadelta T Cells by Bisphosphonates

J. Mönkkönen, M. Rogers, H. Mönkkönen, 2010 .